Page last updated: 2024-08-26

peptide elongation factor 2 and Cirrhosis

peptide elongation factor 2 has been researched along with Cirrhosis in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dyck, JR; Ikeda, Y; Pimentel, DR; Sam, F; Sato, K; Shaw, RJ; Walsh, K1

Other Studies

1 other study(ies) available for peptide elongation factor 2 and Cirrhosis

ArticleYear
Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction.
    The Journal of biological chemistry, 2009, Dec-18, Volume: 284, Issue:51

    Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Antibiotics, Antineoplastic; Atrial Fibrillation; Carrier Proteins; Collagen Type I; Collagen Type II; Fibrosis; Gene Expression Regulation; Heart Atria; Hypertrophy, Left Ventricular; Mice; Mice, Knockout; Myocardium; Organ Specificity; Peptide Elongation Factor 2; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Protein Kinases; Protein Serine-Threonine Kinases; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Messenger; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases

2009